Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2007

S*BIO and A*STAR to Partner on New Compounds to Treat Cancer

  • S*BIO signed a two-year master research collaboration agreement with Singapore’s agency for Science, Technology and Research's (A*STAR) Institute of Molecular and Cell Biology (IMCB) for the discovery and development of multiple compounds for the treatment of cancer.

    Promising compounds may be further developed by A*STAR's newly formed Experimental Therapeutics Centre (ETC) as well as S*BIO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »